NEEDLE FREE INJECTION TECHNOLOGY- AN OVERVIEW

August 29, 2019

Injuries which occur on regular basis in day today routine of hospital and healthcare setups. The Plethora of new injectable products has created new opportunities for physicians to treat areas previously thought to be not reachable.

Spotlight

Vel Vaccines Biosciences

VEL (Variable Epitope Library) vaccine technology was developed to address the need for effective immunization strategies against antigenically variable targets. The main limitation of current technologies is their inability to elicit sustained, protective immune responses against these constantly changing targets. VEL vaccines anticipate large numbers of mutational outcomes in the target and challenge host immune defenses with thousands and tens of thousands of epitopes. Immune systems primed with VEL-vaccines produce unprecedented repertoires of T-cells capable of containing and neutralizing disease caused by antigenically variable targets.

OTHER WHITEPAPERS
news image

Pharma R&D Annual Review 2022 Navigating the Landscape

whitePaper | June 27, 2022

Welcome to Pharmaprojects' 2022 reviews of trends in pharmaceutical R&D. Take a look at the evolution of pharma R&D and in this article, examine the state of play at the start of 2022.

Read More
news image

THE PHARMACEUTICAL INDUSTRY AND GLOBAL HEALTH

whitePaper | January 31, 2022

COVID-19 is an infectious disease caused by a newly discovered coronavirus, which was first identified in December 2019.

Read More
news image

2020 Prescription Drug List

whitePaper | April 7, 2020

The information in this document is designed to help you understand the prescription drug benefits offered under this plan and to compare these benefits to those offered by other plans. Information contained in this summary is designed to help you compare both the value and scope offormulary benefits.

Read More
news image

Winning with biosimilars Opportunities in global markets

whitePaper | March 14, 2022

Over the past several years, biologics have gained significant traction in the pharmaceutical industry, representing more than $150 billion in global sales in 2013. By 2020 they are predicted to generate $290 billion in revenue and comprise 27 percent of the pharmaceutical market.i

Read More
news image

Deck 7 Webinars and Virtual Events

whitePaper | January 1, 2020

If you recognize some of these challenges, download the Deck 7 Webinar & Virtual Events overview to see how we make it easy for busy marketers to run highly successful webinars and virtual events....

Read More
news image

How IPD Can Deliver for Life Sciences

whitePaper | January 1, 2020

Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.

Read More

Spotlight

Vel Vaccines Biosciences

VEL (Variable Epitope Library) vaccine technology was developed to address the need for effective immunization strategies against antigenically variable targets. The main limitation of current technologies is their inability to elicit sustained, protective immune responses against these constantly changing targets. VEL vaccines anticipate large numbers of mutational outcomes in the target and challenge host immune defenses with thousands and tens of thousands of epitopes. Immune systems primed with VEL-vaccines produce unprecedented repertoires of T-cells capable of containing and neutralizing disease caused by antigenically variable targets.

Events